Post-Transplant Lymphoproliferative Disorder Clinical Trials

7 recruitingLast updated: July 25, 2026

There are 7 actively recruiting post-transplant lymphoproliferative disorder clinical trials across 2 countries. Studies span Phase 1, Phase 2. Top locations include Columbus, Ohio, United States, Beijing, China, St Louis, Missouri, United States. Updated daily from ClinicalTrials.gov.


Post-Transplant Lymphoproliferative Disorder Trials at a Glance

7 actively recruiting trials for post-transplant lymphoproliferative disorder are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Columbus, Beijing, and St Louis. Lead sponsors running post-transplant lymphoproliferative disorder studies include Daihong Liu, Timothy Voorhees, and Ohio State University Comprehensive Cancer Center.

Browse post-transplant lymphoproliferative disorder trials by phase

Treatments under study

About Post-Transplant Lymphoproliferative Disorder Clinical Trials

Looking for clinical trials for Post-Transplant Lymphoproliferative Disorder? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Post-Transplant Lymphoproliferative Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Post-Transplant Lymphoproliferative Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Reem Karmali34 enrolled1 locationNCT06723457
Recruiting
Phase 1

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

EBV-Related Lymphoproliferative DisorderPost-Transplant Lymphoproliferative DisorderChronic Kidney Disease Stage 5+2 more
Ohio State University Comprehensive Cancer Center55 enrolled1 locationNCT06741072
Recruiting
Phase 1Phase 2

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Post-Transplant Lymphoproliferative Disorder
Washington University School of Medicine12 enrolled1 locationNCT06040320
Recruiting
Phase 2

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Timothy Voorhees28 enrolled4 locationsNCT05786040
Recruiting
Phase 1Phase 2

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEBV-DNA Viremia
Daihong Liu18 enrolled1 locationNCT07438067
Recruiting
Phase 1Phase 2

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEpstein-Barr Virus Infection
Daihong Liu18 enrolled1 locationNCT07368634
Recruiting
Phase 1

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more
Timothy Voorhees26 enrolled2 locationsNCT06672705